Ventana Medical Systems’ new CONFIRM anti-CD3 (2GV6) – the latest exciting advancement in moving from mouse to Rabbit Monoclonal Primary Antibodies.

CONFIRM anti-CD3 (2GV6) detects CD3 antigen expressed in the cytoplasmic membrane of normal and neoplastic T-cells.

To read a research paper about this new product please click here.